Phase II study of ZYN002 in pediatric and adolescent patients with developmental and epileptic encephalopathies.

Trial Profile

Phase II study of ZYN002 in pediatric and adolescent patients with developmental and epileptic encephalopathies.

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jan 2018 New trial record
    • 03 Jan 2018 According to Zynerba Pharmaceuticals media release, company will initiate this trial in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top